About one month ahead of disclosing Phase II data for DX-88 in hereditary angioedema, Dyax Corp. said the FDA has placed the compound on clinical hold pending answers to the agency's questions regarding animal studies. (BioWorld Today)

News from the FDA that Vicuron Pharmaceuticals Inc.'s new drug application for anidulafungin does not support a label for esophageal candidiasis sent the company's stock reeling Monday. (BioWorld Today)

Two groups of seismologists have made headlines by predicting major temblors in California in the near term, which would put an end to the relative calm that's been enjoyed by the state, tectonically speaking.